Pα+ Psychedelic Bulletin #209: Aussie insurer covers psilocybin for TRD; atai gets $11.4M NIDA grant; Oregon real world psilocybin outcomes; pipeline updates

Psilocybin and other psychedelic development news dominate Pα+ Psychedelic Bulletin #209, with major items spanning funding, commercialization signals, and early outcomes. Australian insurer funding takes center stage, with Australia’s largest private health insurer backing a psilocybin pilot for treatment-resistant depression. The bulletin also highlights atai’s $11.4M NIDA award toward non-hallucinogenic psychedelics aimed at opioid use disorder, specifically targeting 5-HT2A/2C receptor agonism and emphasizing non-hallucinogenic candidate development. For real-world evidence, the bulletin reports Osmind and Bendable sharing outcomes from 88 psilocybin clients in Oregon, positioning the work as a first look at non-trial, real-world results. It closes with a pipeline Bullseye chart update log and additional headlines across the psychedelics sector.